Videos

Joseph Goldberg, MD, discusses the recent joint statement on evidence-based medicine and psychotropic safety.

Our Mood Disorders Section Editor shares his thoughts on this year's biggest clinical trial successes and failures.

The FDA decision to remove the clozapine REMs requirement has left many questions. Chelsie Monroe, MSN, APN, PMHNP-BC, sheds some light on it.

Psychiatric Times Editor in Chief John J. Miller, MD, shares thoughts on psychiatry's response to the recent executive order.

What are the most pressing issues facing psychiatry? Gustavo Alva, MD, FAPA, shares his thoughts.

"Any decent realtor, walking you through a real shithole, chirps on about good bones: This place could be beautiful, right? You could make this place beautiful."

Chelsea Monroe, MSN, APN, PMHNP-BC, discusses the current renaissance in treating schizophrenia.

Celebrate our 40th anniversary with Gustavo Alva, MD, FAPA, our Mood Disorders Section Editor.

Let's process our trauma, grief, and healing from COVID-19.

"I stood by her side, stunned when her breathing stopped..."

Rejoyn, a new app being prescribed as a depression treatment, is an emotional face memory task designed to correct abnormal neural circuits.

Spring is full of religious holidays, each with potential psychosocial meaning...

Dennis S. Charney, MD, discussed the importance of trying and risking failure when studying new potential treatments, as well as the future of treating depression.

Dennis S. Charney, MD, discussed the discovery of ketamine as a rapid-acting treatment for depression, its journey from skepticism to FDA approval, and its impact on mental health care.

"Suddenly, in every tree, an unseen nest where a mountain would be."

René S. Kahn, MD, PhD, discussed the potential artificial intelligence has to advance the field of psychiatry when diagnosing patients and allowing clinicians to focus on the clinical conversation.

Dennis S. Charney, MD, shared how he encouraged front line health care workers at Mount Sinai during the COVID-19 Pandemic.

Time: as important a concern as the economy? H. Steven Moffic, MD, elaborates.

The PREDiCTOR study is trying to develop objective measurements for psychiatric diagnoses.

Margot Rittenhouse, MS, LPCC, discussed how caregivers and clinicians alike can identify warning signs and support adolescents experiencing eating disorders.

Dennis S. Charney, MD, shared how he has fostered success during his tenure as the Dean of the Icahn School of Medicine at Mount Sinai.

Dennis S. Charney, MD, celebrates the 40th anniversary of Psychiatric Times discussing the history of psychiatry and where he hopes the future lies.

A new study from Mount Sinai Health System and IBM Research is investigating the use of AI in developing objective measures for psychiatric diagnoses.

Learn more about the need for closer collaboration between psychiatry and cannabis research to explore its therapeutic potential, mitigate risks, and advance evidence-based mental health treatments.

What challenges, stigma, and barriers are faced by youth in marginalized communities?